Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

The Potential Role of Erythropoietin as a Pleiotropic Agent in Post-cardiac Arrest Syndrome

Author(s): Theodoros Xanthos, Panagiotis V.S. Vasileiou, Sotirios Kakavas, Aggeliki Syggelou and Nicoletta Iacovidou

Volume 17, Issue 15, 2011

Page: [1517 - 1529] Pages: 13

DOI: 10.2174/138161211796197115

Price: $65

Open Access Journals Promotions 2
conference banner
Abstract

Sudden cardiac arrest is a leading cause of death worldwide with survival rates still remaining suboptimal. Unfortunately, most cardiac arrest patients, who achieve return of spontaneous circulation (ROSC), develop a multi-faceted post-cardiac arrest syndrome, including post-cardiac arrest brain injury, myocardial dysfunction, and systemic ischemia/reperfusion response.

Erythropoietin (EPO), the principal hematopoietic hormone regulating erythropoiesis, exhibits diverse cellular effects in nonhematopoietic tissues. Due to its anti-apoptotic, anti-inflammatory, and anti-oxidant properties, as well as its angiogenic action, EPO plays a role in neuroprotection and cardioprotection. In this regard, EPO represents a promising agent in the cardiac arrest setting, based on a therapeutic strategy that focuses on the post-resuscitation phase.

This review aims to provide a comprehensive account of EPOs role in the treatment of each individual component of post-cardiac arrest syndrome.

Keywords: Erythropoietin, Cardiac arrest, Post-cardiac arrest syndrome, Neuroprotection, Cardioprotection, Anti-oxidant, hematopoietic, heterotrimer, dysfunction, reperfusion, homeostasis, cardiopulmonary, leukocytes, apoptotic, P-selectin, astrocytes, hypoxic, necrosis

« Previous

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy